Literature DB >> 14579086

Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease.

Marta Encinas1, Ramón De Juan, Alberto Marcos, Pedro Gil, Ana Barabash, Cristina Fernández, Carmen De Ugarte, José Antonio Cabranes.   

Abstract

Patients diagnosed with mild cognitive impairment (MCI) have a higher risk of developing Alzheimer's disease (AD). However, not all such patients develop this kind of dementia. The purpose of this prospective study was to assess whether regional cerebral blood flow (rCBF) patterns measured with technetium-99m ethyl cysteinate dimer single-photon emission tomography ((99m)Tc-ECD SPET) in patients suffering from MCI are useful in predicting progression to AD. The study group comprised 42 patients who fulfilled MCI criteria according to the International Psychogeriatric Association and the Alzheimer's Disease Cooperative Study. rCBF was calculated in 16 regions of interest (ROIs). All patients were clinically assessed for 1-3 years. Twenty-one developed AD (group I) while the initial diagnosis of MCI was retained in the other 21 (group II). ROC curves were designed, and sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios were determined for each ROI. Compared with group II (MCI), group I (AD) showed a significant reduction of relative blood flow (RBF), ranging from 7% to 10%, in the following areas: right and left prefrontal, right and left frontal, right and left parietal, right and left temporal, right and left frontoparietotemporal and left posterior lateral temporal. Left prefrontal, left frontal and left parietal areas showed sensitivities and specificities higher than 75% and areas below the ROC curve close to 80%. This study shows that RBF patterns in the right and left prefrontal, right and left frontal and left parietal areas are sensitive early markers of progression towards AD. Reduction of rCBF in the medial temporal and anterior lateral temporal cortex has no value as a predictor since it also occurs in patients with MCI who remain stable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14579086     DOI: 10.1007/s00259-003-1277-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  44 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

3.  Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment.

Authors:  P W Schofield; K Marder; G Dooneief; D M Jacobs; M Sano; Y Stern
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

4.  [Cerebral blood flow of patients with age-associated memory impairment and the early stage of Alzheimer's disease. A study by SPECT using the ARG method].

Authors:  A Ishiwata; S Kitamura; A Nagazumi; A Terashi
Journal:  Nihon Ika Daigaku Zasshi       Date:  1998-04

5.  ICD-10 mild cognitive disorder: its outcome three years later.

Authors:  H Christensen; A S Henderson; A E Korten; A F Jorm; P A Jacomb; A J Mackinnon
Journal:  Int J Geriatr Psychiatry       Date:  1997-05       Impact factor: 3.485

6.  Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss.

Authors:  A Bozoki; B Giordani; J L Heidebrink; S Berent; N L Foster
Journal:  Arch Neurol       Date:  2001-03

7.  Cognitive markers preceding Alzheimer's dementia in the healthy oldest old.

Authors:  D B Howieson; A Dame; R Camicioli; G Sexton; H Payami; J A Kaye
Journal:  J Am Geriatr Soc       Date:  1997-05       Impact factor: 5.562

8.  Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT.

Authors:  D Kogure; H Matsuda; T Ohnishi; T Asada; M Uno; T Kunihiro; S Nakano; M Takasaki
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

9.  Independent predictors of cognitive decline in healthy elderly persons.

Authors:  Scott Marquis; M Milar Moore; Diane B Howieson; Gary Sexton; Haydeh Payami; Jeffrey A Kaye; Richard Camicioli
Journal:  Arch Neurol       Date:  2002-04

10.  Single photon emission computed tomography in Alzheimer's disease. Abnormal iofetamine I 123 uptake reflects dementia severity.

Authors:  K A Johnson; B L Holman; S P Mueller; T J Rosen; R English; J S Nagel; J H Growdon
Journal:  Arch Neurol       Date:  1988-04
View more
  27 in total

1.  A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease.

Authors:  Montserrat Alegret; Gemma Cuberas-Borrós; Georgina Vinyes-Junqué; Ana Espinosa; Sergi Valero; Isabel Hernández; Isabel Roca; Agustín Ruíz; Maitée Rosende-Roca; Ana Mauleón; James T Becker; Joan Castell-Conesa; Lluís Tárraga; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment.

Authors:  Montserrat Alegret; Gemma Cuberas-Borrós; Ana Espinosa; Sergi Valero; Isabel Hernández; Agustín Ruíz; James T Becker; Maitée Rosende-Roca; Ana Mauleón; Oscar Sotolongo; Joan Castell-Conesa; Isabel Roca; Lluís Tárraga; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Memory-provoked rCBF-SPECT as a diagnostic tool in Alzheimer's disease?

Authors:  Torbjörn Sundström; Eva Elgh; Anne Larsson; Birgitta Näsman; Lars Nyberg; Katrine A Riklund
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

4.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

5.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- for.

Authors:  Kazunari Ishii; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 6.  Interventions for heart disease and their effects on Alzheimer's disease.

Authors:  Benjamin Wolozin; Martin M Bednar
Journal:  Neurol Res       Date:  2006-09       Impact factor: 2.448

7.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

8.  Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment.

Authors:  A Caroli; C Testa; C Geroldi; F Nobili; L R Barnden; U P Guerra; M Bonetti; G B Frisoni
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

9.  Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study.

Authors:  Flavio Nobili; Giovanni B Frisoni; Florence Portet; Frans Verhey; Guido Rodriguez; Anna Caroli; Jacques Touchon; Piero Calvini; Silvia Morbelli; Fabrizio De Carli; Ugo P Guerra; Laura A Van de Pol; Pieter-Jelle Visser
Journal:  J Neurol       Date:  2008-08-01       Impact factor: 4.849

10.  Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease.

Authors:  Montse Alegret; Mercè Boada-Rovira; Georgina Vinyes-Junqué; Sergi Valero; Ana Espinosa; Isabel Hernández; Gemma Modinos; Maitee Rosende-Roca; Ana Mauleón; James T Becker; Lluís Tárraga
Journal:  J Clin Exp Neuropsychol       Date:  2009-01-14       Impact factor: 2.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.